News & Updates

Is it safe to administer lacosamide and levetiracetam via IV push?

06 Oct 2023

Use of undiluted lacosamide and levetiracetam to prevent seizures does not result in significant adverse events when administered via intravenous (IV) push over 5 min, according to a study. This approach appears to be a safe alternative form of administration to intermittent infusion.

Is it safe to administer lacosamide and levetiracetam via IV push?

06 Oct 2023

Liraglutide vs semaglutide: Which is a better GLP-1 RA for diabetic veterans?

06 Oct 2023

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) liraglutide and semaglutide are both effective at lowering haemoglobin A1c (A1c) among veterans with type 2 diabetes mellitus (T2DM), reports a recent study, which provides insights into key considerations for this population.

Liraglutide vs semaglutide: Which is a better GLP-1 RA for diabetic veterans?

06 Oct 2023

$Early-life exposure to acid suppressants may up risk of fractures during childhood$

Early-life exposure to acid suppressants may up risk of fractures during childhood

06 Oct 2023

Exposure to acid-suppressive therapy during the first year of life appear to come with a small but significant increase in the risk of fractures, according to a study.

Early-life exposure to acid suppressants may up risk of fractures during childhood

06 Oct 2023

“Forever chemicals” a culprit in delayed puberty in girls

05 Oct 2023 by

Exposure to per- and polyfluoroalkyl substances (PFAS), dubbed “forever chemicals,” may contribute to a delay in puberty through its effects on body mass index (BMI) and sex hormones, as shown in a study.

“Forever chemicals” a culprit in delayed puberty in girls

05 Oct 2023

Muvalaplin for lowering Lp(a) succeeds in early-phase trial

05 Oct 2023

The selective small molecule inhibitor of lipoprotein(a) (Lp[a]) formation muvalaplin helps reduce Lp(a) levels by up to 65 percent without safety and tolerability signals, as shown in the results of a phase I trial.

Muvalaplin for lowering Lp(a) succeeds in early-phase trial

05 Oct 2023

5-MTHF improves portal pressure reduction with propranolol in cirrhosis patients

04 Oct 2023

Treatment with 5-methyltetrahydrofolate (5-MTHF) significantly enhances the effect of propranolol in reducing hepatic venous pressure gradient (HVPG) in patients with cirrhosis and portal hypertension, a recent study has shown.

5-MTHF improves portal pressure reduction with propranolol in cirrhosis patients

04 Oct 2023

Combination therapy with olmesartan safe, effective in advanced hypertension

04 Oct 2023 by

Use of olmesartan in a combination therapy for advanced hypertension results in similar cardiovascular outcomes, including myocardial infarction (MI), relative to active comparators, according to a study. Additionally, there is no convincing evidence that olmesartan is harmful to patients with hypertension.

Combination therapy with olmesartan safe, effective in advanced hypertension

04 Oct 2023

Ranitidine use not linked to increased cancer incidence

04 Oct 2023

Individuals with ranitidine exposure do not appear to be at increased risk of cancer compared with those who have exposure to other histamine-2 receptor antagonists (H2RAs), according to a study.

Ranitidine use not linked to increased cancer incidence

04 Oct 2023

Dabrafenib-trametinib combo improves response in BRAF V600-mutant paediatric glioma

04 Oct 2023 by

First-line treatment with dabrafenib plus trametinib significantly increased overall response rate (ORR) in paediatric patients with low-grade glioma harbouring BRAF V600 mutations compared with standard chemotherapy, according to a recent study.

Dabrafenib-trametinib combo improves response in BRAF V600-mutant paediatric glioma

04 Oct 2023

Heavy alcohol use among hepatitis C patients does not weaken response to DAAs

03 Oct 2023 by

Among patients with hepatitis C virus (HCV) infection, the likelihood of achieving sustained virologic response (SVR) with direct-acting antivirals (DAAs) does not appear to be reduced among those who use alcohol or have alcohol use disorder (AUD), according to a study.

Heavy alcohol use among hepatitis C patients does not weaken response to DAAs

03 Oct 2023

News & Updates

Filter by Specialty:

Specialty:

Is it safe to administer lacosamide and levetiracetam via IV push?

Is it safe to administer lacosamide and levetiracetam via IV push?

Liraglutide vs semaglutide: Which is a better GLP-1 RA for diabetic veterans?

Liraglutide vs semaglutide: Which is a better GLP-1 RA for diabetic veterans?

Early-life exposure to acid suppressants may up risk of fractures during childhood

Early-life exposure to acid suppressants may up risk of fractures during childhood

“Forever chemicals” a culprit in delayed puberty in girls

“Forever chemicals” a culprit in delayed puberty in girls

Muvalaplin for lowering Lp(a) succeeds in early-phase trial

Muvalaplin for lowering Lp(a) succeeds in early-phase trial

5-MTHF improves portal pressure reduction with propranolol in cirrhosis patients

5-MTHF improves portal pressure reduction with propranolol in cirrhosis patients

Combination therapy with olmesartan safe, effective in advanced hypertension

Combination therapy with olmesartan safe, effective in advanced hypertension

Ranitidine use not linked to increased cancer incidence

Ranitidine use not linked to increased cancer incidence

Dabrafenib-trametinib combo improves response in BRAF V600-mutant paediatric glioma

Dabrafenib-trametinib combo improves response in BRAF V600-mutant paediatric glioma

Heavy alcohol use among hepatitis C patients does not weaken response to DAAs

Heavy alcohol use among hepatitis C patients does not weaken response to DAAs